Aligos Therapeutics, Inc. (ALGS) vs Nephros, Inc. (NEPH)
A side-by-side comparison of Aligos Therapeutics, Inc. and Nephros, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALGS
Aligos Therapeutics, Inc.
$5.38HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
NEPH
Nephros, Inc.
$3.02HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — ALGS vs NEPH
growth of $100 · dividends reinvested · last 6yALGS -98.5% (-50.6%/yr)NEPH -48.2% (-10.4%/yr)NEPH compounded faster over this window
Log scale — wide-divergence pair
ALGS NEPH
ALGS vs NEPH: by the numbers
- •ALGS is the larger company ($33M vs $33M market cap).
- •NEPH is profitable (8.38% net margin) while ALGS runs a net loss (-241.01%).
- •NEPH grew revenue faster over the past five years (16.99% vs -15.85% CAGR).
Metrics side by side
Valuation
| Metric | ALGS | NEPH |
|---|---|---|
| P/E ratio | N/A | 19.03 |
| Forward P/E | N/A | 19.28 |
| P/S ratio | 1.06 | 1.58 |
| P/B ratio | 1.04 | 2.74 |
| EV / EBITDA | N/A | 16.41 |
Profitability
| Metric | ALGS | NEPH |
|---|---|---|
| Gross margin | 57.46% | 60.31% |
| Operating margin | -4024.93% | 7.92% |
| Net margin | -241.01% | 8.38% |
| ROE | -238.24% | 14.51% |
| ROIC | -207.97% | 12.67% |
Growth (annualized)
| Metric | ALGS | NEPH |
|---|---|---|
| Revenue CAGR (5Y) | -15.85% | 16.99% |
| Total return CAGR (5Y) | -57.15% | -15.93% |
Frequently asked
- Which has grown faster, ALGS or NEPH?
- Over the past five years, NEPH grew revenue faster — ALGS at a -15.85% CAGR versus NEPH at 16.99%.
- Is ALGS or NEPH more profitable?
- NEPH runs the higher net margin — ALGS at -241.01% versus NEPH at 8.38%.
- How have ALGS and NEPH total returns compared?
- Over the past 5 years, ALGS delivered -57.15% and NEPH delivered -15.93% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Nephros P/E ratioAligos Therapeutics ROENephros ROEAligos Therapeutics operating marginNephros operating marginAligos Therapeutics revenue growthNephros revenue growthAligos Therapeutics free cash flowNephros free cash flow
Aligos Therapeutics & Nephros appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.